$9.48
0.96% yesterday
Nasdaq, Dec 24, 07:00 pm CET
ISIN
US0352551081
Symbol
ANIK

Anika Therapeutics, Inc. Stock price

$9.48
-0.39 3.95% 1M
-1.75 15.58% 6M
-6.98 42.41% YTD
-6.85 41.95% 1Y
-18.41 66.01% 3Y
-33.72 78.06% 5Y
-29.83 75.88% 10Y
-2.19 18.77% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.09 0.96%
ISIN
US0352551081
Symbol
ANIK
Industry

Key metrics

Basic
Market capitalization
$136.7m
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.2 | 1.2
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
76.0%
Return on Equity
-36.6%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
$112.8m | $113.3m
EBITDA
$-6.2m | $2.4m
EBIT
$-12.4m | $-15.0m
Net Income
$-33.0m | -
Free Cash Flow
$650.0k
Growth (TTM | estimate)
Revenue
-31.3% | -5.6%
EBITDA
-266.1% | -58.8%
EBIT
-101.6% | -551.4%
Net Income
66.1% | -
Free Cash Flow
146.4%
Margin (TTM | estimate)
Gross
54.7%
EBITDA
-5.5% | 2.1%
EBIT
-11.0%
Net
-29.3% | -
Free Cash Flow
0.6%
More
EPS
$-2.3
FCF per Share
-
Short interest
3.6%
Employees
288
Rev per Employee
$420.0k
Show more

Is Anika Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Anika Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Anika Therapeutics, Inc. forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Anika Therapeutics, Inc. forecast:

Buy
88%
Hold
13%

Financial data from Anika Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
113 113
31% 31%
100%
- Direct Costs 51 51
17% 17%
45%
62 62
40% 40%
55%
- Selling and Administrative Expenses 48 48
39% 39%
43%
- Research and Development Expense 26 26
15% 15%
23%
-6.18 -6.18
266% 266%
-5%
- Depreciation and Amortization 6.22 6.22
37% 37%
6%
EBIT (Operating Income) EBIT -12 -12
102% 102%
-11%
Net Profit -33 -33
66% 66%
-29%

In millions USD.

Don't miss a Thing! We will send you all news about Anika Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Anika Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
20 days ago
NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Anika Therapeutics, Inc. (“Anika” or the “Company”) (NASDAQ:ANIK). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.
Neutral
Seeking Alpha
about 2 months ago
Anika Therapeutics, Inc. ( ANIK ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Matt Hall Cheryl Blanchard - President, CEO & Director Stephen Griffin - Executive VP, CFO & COO Conference Call Participants Michael Petusky - Barrington Research Associates, Inc., Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to Anika's third quar...
Neutral
GlobeNewsWire
about 2 months ago
Commercial Channel revenue up 22% with continued strong Integrity ™ Implant System and Hyalofast® growth, and double-digit International OA Pain Management growth Third and final Hyalofast PMA module filed and data released Cingal® achieved commercial milestone of more than one million injections worldwide since 2016 Reaffirming Fiscal 2025 guidance and long-term outlook and commencing a $15 mi...
More Anika Therapeutics, Inc. News

Company Profile

Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.

Head office United States
CEO Cheryl Blanchard
Employees 288
Founded 1992
Website anika.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today